During these challenging times, it is important for us to do
everything we can to ensure the safety of our patients and the continuity of all
ongoing projects. GCT remains fully operational during the outbreak with our employees
available in the USA, Europe, and Asia.  We
are conducting business as usual while adapting, as needed in these unusual and
unprecedented circumstances.

We are closely monitoring government regulations and
guidelines to stay compliant and help slow the spread of COVID-19.  GCT is following the latest recommendations
issued by the US Food and Drug Administration (FDA), the Centers for Disease
Control and Prevention (CDC), the European Commission, the European Medicines
Agency (EMA) and the Heads of Medicines Agencies (HMA).  We are working to proactively assess each
study’s needs in this fluid situation to keep to our client’s timelines and

I would like to thank our partners for their trust in us and
our employees for their dedication. Please do not hesitate to reach out to us
with your questions and requests — we remain open and at your disposal.

Best Regards,

Eugene Selivra, MD

Chief Executive Officer

Global Clinical Trials